Ligand Pharmaceuticals (LGND) Payables (2010 - 2026)

Ligand Pharmaceuticals has disclosed Payables across 17 years of filings, most recently posting $5.3 million for Q1 2026.

• Payables for Q1 2026 came in at $5.3 million, down 1.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (down 1.9% YoY), and the FY2025 annual result was $3.2 million, down 38.12% from the prior year.
• Payables came in at $5.3 million for Q1 2026 at Ligand Pharmaceuticals, up from $3.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $19.2 million in Q2 2022 to a low of $1.8 million in Q2 2024.
• The 5-year median for Payables is $5.3 million (2026), against an average of $6.3 million.
• Across the five-year window, Payables plunged 84.42% in 2023 and surged 378.75% in 2025, its largest moves.
• Ligand Pharmaceuticals' Payables stood at $5.3 million in 2022, then plunged by 54.27% to $2.4 million in 2023, then surged by 115.62% to $5.2 million in 2024, then plunged by 38.12% to $3.2 million in 2025, then soared by 62.57% to $5.3 million in 2026.
• The last three Payables figures came in at $5.3 million (Q1 2026), $3.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.